Pliant Therapeutics Statistics
Share Statistics
Pliant Therapeutics has 60.85M shares outstanding. The number of shares has increased by 1.51% in one year.
| Shares Outstanding | 60.85M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.79% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 53.75M |
| Failed to Deliver (FTD) Shares | 400 |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 7.22M, so 11.86% of the outstanding shares have been sold short.
| Short Interest | 7.22M |
| Short % of Shares Out | 11.86% |
| Short % of Float | 13.42% |
| Short Ratio (days to cover) | 17.04 |
Valuation Ratios
The PE ratio is -6.59 and the forward PE ratio is -3.44.
| PE Ratio | -6.59 |
| Forward PE | -3.44 |
| PS Ratio | 673.04 |
| Forward PS | 130.3 |
| PB Ratio | 2.25 |
| P/FCF Ratio | -9.07 |
| PEG Ratio | n/a |
Enterprise Valuation
Pliant Therapeutics Inc. has an Enterprise Value (EV) of 1.01B.
| EV / Earnings | -6.27 |
| EV / Sales | 640.22 |
| EV / EBITDA | -6.39 |
| EV / EBIT | -5.49 |
| EV / FCF | -8.62 |
Financial Position
The company has a current ratio of 17.72, with a Debt / Equity ratio of 0.02.
| Current Ratio | 17.72 |
| Quick Ratio | 17.72 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.34 |
| Cash Flow / Debt | -10.23 |
| Interest Coverage | -145.34 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -37.97%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.32% |
| Return on Capital (ROIC) | -37.97% |
| Revenue Per Employee | 9.52K |
| Profits Per Employee | -971.90K |
| Employee Count | 166 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -21.24% in the last 52 weeks. The beta is 1.09, so Pliant Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.09 |
| 52-Week Price Change | -21.24% |
| 50-Day Moving Average | 13.8 |
| 200-Day Moving Average | 13.22 |
| Relative Strength Index (RSI) | 48.49 |
| Average Volume (20 Days) | 459.56K |
Income Statement
In the last 12 months, Pliant Therapeutics had revenue of $1.58M and earned -$161.34M in profits. Earnings per share was $-2.75.
| Revenue | 1.58M |
| Gross Profit | 1.58M |
| Operating Income | -184.15M |
| Net Income | -161.34M |
| EBITDA | -158.23M |
| EBIT | -184.15M |
| Earnings Per Share (EPS) | -2.75 |
Balance Sheet
The company has $63.23M in cash and $11.37M in debt, giving a net cash position of $51.86M.
| Cash & Cash Equivalents | 63.23M |
| Total Debt | 11.37M |
| Net Cash | 51.86M |
| Retained Earnings | -499.75M |
| Total Assets | 445.67M |
| Working Capital | 370.08M |
Cash Flow
In the last 12 months, operating cash flow was -$116.36M and capital expenditures -$921.00K, giving a free cash flow of -$117.28M.
| Operating Cash Flow | -116.36M |
| Capital Expenditures | -921.00K |
| Free Cash Flow | -117.28M |
| FCF Per Share | -2 |
Margins
Gross margin is 100%, with operating and profit margins of -11.65K% and -10.21K%.
| Gross Margin | 100% |
| Operating Margin | -11.65K% |
| Pretax Margin | -10.21K% |
| Profit Margin | -10.21K% |
| EBITDA Margin | -10.01K% |
| EBIT Margin | -11.65K% |
| FCF Margin | -7.42K% |
Dividends & Yields
PLRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -20.83% |
| FCF Yield | -14.6% |
Analyst Forecast
The average price target for PLRX is $41, which is 210.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $41 |
| Price Target Difference | 210.6% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 2.53 |
| Piotroski F-Score | 2 |